Previous 10 | Next 10 |
There's big news for Guardant Health (NASDAQ: GH) shareholders today -- but disappointing news also. This morning, analysts at investment bank Craig-Hallum announced a switch in their bets on cancer-screening biopsy companies, downgrading shares of Exact Sciences (NASDAQ: ...
Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...
Summary Guardant Health derives most of its revenue from FDA-approved liquid-biopsy services as opposed to CLIA-waived laboratory-developed tests "LDT". As the FDA prepares to extend its regulatory arm over LDT, it might be a good idea to shift your investment exposure to companie...
Summary We are bullish on the at-home testing healthcare market but bearish for retail value investors on Fulgent Genetics until growth and momentum improve. They reported revenue growth and profits, hold a lot of cash, but face a year of possible slowing revenue and significantly...
Summary As EXAS continues shifting its business models from "growth at all costs" to "profitable growth" in response to rising capital costs, its sales will expand at a slower pace. Despite the expected normalization in growth, in my view, the market will likely reward improved ma...
Exact Sciences schedules third quarter 2022 earnings call PR Newswire MADISON, Wis. , Oct. 10, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s tough to follow anyone’s lead in investing in the stock market these days. Many top stock pickers, including Cathie Wood of ARK Invest, have had a terrible year in the equity markets. Cathie Wood focuses ...
Summary ARKG's objective is compelling and inoffensive, but their current approach to realizing it feels too vague and scattershot. While the larger names in the portfolio do appear to belong, the bulk of the fund is in up-and-coming names, pre-profit, that feel like acquisition i...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re looking for cheap Cathie Wood stocks to buy in October, you might want to stay away from the controversial portfolio manager’s latest fund. On Sept. 27, Wood’s investment firm, Ark ...
Summary There is a high chance that the Illumina, Inc.-Grail deal would collapse after European regulators decide to block the acquisition. Without Grail, I believe Illumina will find it hard to maintain growth in light of disruptions in its end markets, namely the clinical gene t...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...